Drug Profile

DP 3311

Alternative Names: DP-3311; Lutetium 177 tumour targeting molecule; N.c.a. 177Lu-TTM; n.c.a. ¹⁷⁷Lu-TTM

Latest Information Update: 28 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Isotopen Technologien Munchens
Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Jun 2024 No recent reports of development identified for preclinical development in Glioblastoma in Germany (Parenteral)
20 May 2020 DP 3311 is available for licensing as of 20 May 2020. https://itm-radiopharma.com/itm-partnering-opportunities
15 May 2020 Preclinical trials in Glioblastoma in Germany (Parenteral), prior to May 2020 (Isotopen Technologien Munchens pipeline, May 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com